20:08 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Patient sample and mouse studies suggest inhibiting adrenergic receptors , PGR , cortisol receptor GR-2 and/or CHRNB2 could help treat post-stroke Listeria monocytogenes infection. Post-stroke patients had lower numbers of circulating peripheral...
07:00 , Sep 25, 2014 |  BC Innovations  |  Targets & Mechanisms

ALK7's obese functions

Reduced b- adrenergic signaling has long been associated with obesity, but the likelihood of triggering cardiovascular side effects has prevented companies from targeting the pathway for weight control. Now, a new-and possibly safer-way to upregulate...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of sympathetic nervous system activation in metabolic syndrome A new mouse model could help guide development of therapies that target the sympathetic nervous...
07:00 , Aug 1, 2013 |  BC Innovations  |  Targets & Mechanisms

Prostate cancer's nerves

In prostate cancer, a handful of companies are racing to develop third-generation antiandrogen therapeutics that overcome resistance mechanisms that render first- and second-generation molecules ineffective. 1,2 The problem is that any direct attack on the...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Adrenergic receptors; CD1D A study in mice suggests antagonizing adrenergic receptors could reduce bacterial infection after stroke. In a mouse...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a topical cream targeting alpha adrenergic receptors on...
00:21 , Jul 20, 2011 |  BC Extra  |  Company News

Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 ,...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-206 trial in 85 patients with moderate to severe erythema showed that V-101 met the primary endpoint of significantly reducing facial erythema from baseline over a 12 hour period...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-202 trial in 183 patients with moderate to severe erythema showed that once-daily 0.1% and 0.15% V-101 for 28 days met the primary endpoint of significantly reducing facial erythema...